Allogene upgraded by Robert W. Baird with a new price target
$ALLO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Robert W. Baird upgraded Allogene from Neutral to Outperform and set a new price target of $12.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/8/2024 | $13.00 → $11.00 | Outperform | Oppenheimer |
| 5/31/2024 | $11.00 | Overweight | Piper Sandler |
| 1/5/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 1/5/2024 | Buy → Neutral | Guggenheim | |
| 12/8/2023 | $7.00 | Buy | Citigroup |
| 12/8/2023 | Buy | Citigroup | |
| 6/26/2023 | $28.00 | Outperform | Oppenheimer |
| 3/21/2023 | $6.00 | Mkt Perform | Bernstein |
8-K - Allogene Therapeutics, Inc. (0001737287) (Filer)
10-Q - Allogene Therapeutics, Inc. (0001737287) (Filer)
8-K - Allogene Therapeutics, Inc. (0001737287) (Filer)
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in two upcoming investor conferences in December. The Company is also announcing that the presentation time for the upcoming Jefferies London Healthcare conference on November 20, 2024 has changed. TIME UPDATE: Jefferies London Healthcare ConferenceWednesday, November 20, 202411:30AM GMT/ 6:30AM ET The Citizens JMP Hematology and Oncology Summit (Virtual)Monday, December 2, 20248:00AM PT/11:00AM
ALLO-329 Induces Deep, Transient Depletion of CD19+ B Cells and CD70+ T Cells, and Reduction in IgG and IgM without Lymphodepletion in Humanized Murine ModelsProprietary Dagger® Technology Enables ALLO-329 to Overcome Rejection and Expand the Presence of Alloreactive T CellsPresented Data Demonstrates that ALLO-329 Could Be Effective in Treating Autoimmune Diseases with Reduced or No Lymphodepleting ChemotherapyALLO-329 Investigational New Drug (IND) Submission Planned for Q1 2025 SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) produc
Cemacabtagene Ansegedleucel (Cema-Cel): 1L Consolidation Large B-Cell Lymphoma (LBCL) Pivotal Phase 2 ALPHA3 Trial Continuing with Site Activation and Patient ScreeningLymphodepletion Selection Planned for Mid-2025Enrollment Completion Expected in 1H 2026 with Primary EFS Data by YE 2026Potential BLA Submission in 2027 ALLO-329 in Autoimmune Disease (AID) Pre-Clinical Data Highlighting the Potential of ALLO-329 to be Presented at the American College of Rheumatology (ACR) ConvergenceCD19/CD70 Dual CAR is Specifically Designed to Address Both the B-cell and T-cell Dysfunction Implicated in Autoimmune DiseasesCD70 CAR with Clinically Validated Dagger® Technology Aims to Reduce or Eliminate the
SC 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)
SC 13G - Allogene Therapeutics, Inc. (0001737287) (Subject)
SC 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and was the former CTO of Allog
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, has appointed Geoffrey Parker as Executive Vice President, Chief Financial Officer. Mr. Parker will oversee the Company's financial operations and business strategy and will serve as a member of the Leadership Team. "Geoff's extensive experience in biotechnology across all aspects of finance and business development strategy will be of tremendous value to Allogene as we advance our critical pipeline assets and explore new opportunities," said David Chang, M.D., Ph.D.
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that Earl Douglas has been appointed as General Counsel. Mr. Douglas will oversee all aspects of the Company's legal function and serve as a member of the Leadership Team. "We are excited to welcome Earl who brings a tenure of experience guiding publicly-traded biotech companies on complex legal issues, corporate strategy and transactions," said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. "I also want to th
Oppenheimer resumed coverage of Allogene with a rating of Outperform and set a new price target of $11.00 from $13.00 previously
Piper Sandler initiated coverage of Allogene with a rating of Overweight and set a new price target of $11.00
JMP Securities downgraded Allogene from Mkt Outperform to Mkt Perform
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
Cemacabtagene Ansegedleucel (Cema-Cel): 1L Consolidation Large B-Cell Lymphoma (LBCL) Pivotal Phase 2 ALPHA3 Trial Continuing with Site Activation and Patient ScreeningLymphodepletion Selection Planned for Mid-2025Enrollment Completion Expected in 1H 2026 with Primary EFS Data by YE 2026Potential BLA Submission in 2027 ALLO-329 in Autoimmune Disease (AID) Pre-Clinical Data Highlighting the Potential of ALLO-329 to be Presented at the American College of Rheumatology (ACR) ConvergenceCD19/CD70 Dual CAR is Specifically Designed to Address Both the B-cell and T-cell Dysfunction Implicated in Autoimmune DiseasesCD70 CAR with Clinically Validated Dagger® Technology Aims to Reduce or Eliminate the
Conference Call and Webcast Scheduled for November 7, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report third quarter 2024 financial results and provide a business update on November 7, 2024, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. Listen-Only WebcastThe listen-only webcast will be made available on the Company's website at ww
Cemacabtagene Ansegedleucel (Cema-Cel): 1L Consolidation in Large B-Cell Lymphoma (LBCL) Pivotal Phase 2 ALPHA3 Trial Initiated in June 2024Patient Screening for Minimal Residual Disease (MRD) and Enrollment Proceeding as Planned with Ten Community and Academic Sites Opened to Date Across the USEnrollment Completion Expected in 1H 2026 and Potential BLA Submission in 2027 ALLO-329 in Autoimmune Disease (AID) Investigational New Drug (IND) Application for Next-Generation CD19/CD70 Dual CAR with Dagger® Technology Designed for AID on Track for Q1 2025 with Proof-of-Concept Data Expected by YE 2025 ALLO-316 in Renal Cell Carcinoma (RCC) Phase 1 TRAVERSE Data Update Including Details on the Diag
A revolutionary cell-based gene therapy is showing promise for treating autoimmune diseases. Professor Georg Schett, a rheumatologist at University Hospital Erlangen in eastern Germany, used chimeric antigen receptor (CAR-T) cell therapy, typically used for blood cancers, for autoimmune conditions like lupus, when the immune system attacks healthy cells and tissues by mistake. This attack causes inflammation. The Financial Times writes that the early success of CAT-T therapy has reignited discussions about its potential beyond blood cancers, though challenges remain. Professor Georg Schett noted that this approach could revolutionize autoimmune disease treatment, providing a one-tim
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, Part of the OneOncology Network; and Norton Cancer InstituteALPHA3 Will be the First Pivotal Trial to Offer CAR T as Part of First Line (1L) Treatment at Community Cancer Centers, Where 80% of Patients Receive CareALPHA3 Expected to Complete Enrollment in 1H 2026; Potential BLA Submission in 2027
ALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure Rates First Prospective Trial to Incorporate the Foresight Diagnostics's Investigational CLARITY™ Test to Identify Patients with LBCL Who Have Minimal Residual Disease (MRD) and are Likely to Relapse Following Standard 1L TreatmentUnique Profile of Investigational AlloCAR T™ Products May Expand Access to CAR T within Community Cancer Centers where Most 1L Patients are ManagedALPHA3 Expected to Complete Enrollment in 1H 2026; BLA Submission Anticipated in 2027